Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;7(10):e12831.
doi: 10.5812/jjm.12831. Epub 2014 Oct 1.

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

Zohreh Aminzadeh  1 , Davood Yadegarynia  2 , Alireza Fatemi  2 , Elham Tahmasebian Dehkordi  2 , Saeed Azad Armaki  2
Affiliations

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

Zohreh Aminzadeh et al. Jundishapur J Microbiol. 2014 Oct.

Abstract

Background: New data indicates that vancomycin may be less effective against methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibition concentration (MIC) within a sensitive range.

Objectives: The aim of this study was to determine the distribution of the vancomycin MIC between MRSA strains and observe the difference in mortality between patients, while the influence of changes in MIC on the efficacy of vancomycin was also examined.

Patients and methods: A routine date-based study was conducted on 41 MRSA isolates in a hospital in Tehran, Iran. The isolates were assessed for MIC by using the E-test method, and results were categorized into three groups: A (MIC < 1.5 μg/mL), B (1.5 ≤ MIC < 2 μg/mL) and C (MIC ≥ 2 μg/mL) MRSA.

Results: Group A was the most common group, followed by groups C and B. Although there was no statistically significant difference between patients' mortality with the MIC group, the mortality rate of group A was higher than C and B.

Conclusions: Regarding Clinical and Laboratory Standards Institute (CLSI) definition for vancomycin susceptibility (MIC < 2 μg/mL), it seems that vancomycin may not be considered as the best antibiotic in order to treat heteroresistant vancomycin intermediate S. aureus (hVISA) and vancomycin sensitive S. aureus (VSSA) infections, and a new breakpoint for vancomycin and alternative antibiotics should be considered.

Keywords: Methicillin Resistant; Minimum Inhibitory Concentration; Mortality; Staphylococcus aureus; Vancomycin.

PubMed Disclaimer

References

    1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–44. doi: 10.1001/archinte.166.19.2138. - DOI - PubMed
    1. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85. doi: 10.1016/S0196655304005425. - DOI - PubMed
    1. Shukla SK. Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res. 2005;3(2):57–60. - PMC - PubMed
    1. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006;42 Suppl 1:S51–7. doi: 10.1086/491714. - DOI - PubMed
    1. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350(9092):1670–3. doi: 10.1016/S0140-6736(97)07324-8. - DOI - PubMed

LinkOut - more resources